top of page
Recent Posts

FDA Approves Crizotinib for Pediatric ALK+ ALCL Indication

Crizotinib—a tyrosine kinase inhibitor with activity against ALK, ROS1, and MET—was granted FDA approval for use in pediatric patients with relapsed or refractory ALK-positive anaplastic large cell lymphoma.

Read more:

Search By Tags
bottom of page